Wedbush Keeps Their Buy Rating on Lexicon Pharmaceuticals


In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Lexicon Pharmaceuticals (NASDAQ: LXRX), with a price target of $42. The company’s shares opened today at $13.02.

According to TipRanks.com, Moussatos is a 4-star analyst with an average return of 10.2% and a 44.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

Lexicon Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $42.

See today’s analyst top recommended stocks >>

Based on Lexicon Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $42.08 million. In comparison, last year the company had a GAAP net loss of $34.89 million.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LXRX in relation to earlier this year. Earlier this month, James Tessmer, the VP, Finance & Accounting of LXRX sold 10,000 shares for a total of $129,000.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It also offers programs in clinical development for diabetes, irritable bowel syndrome, and carcinoid syndrome.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts